ACTOplus met XR approved for type 2 diabetes

ACTOplus met XR (pioglitazone HCl/metformin HCl extended-release tablets, from Takeda) has been FDA approved as an adjunct to diet and exercise for the treatment of type 2 diabetes. ACTOplus met XR is indicated for adults with type 2 diabetes who are already treated with Actos (pioglitazone HCl tablets, from Takeda) and metformin or who have inadequate glycemic control on Actos or metformin alone.

ACTOplus met XR is expected to be available later this year.

For more information call (877) 825-3327 or visit